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Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal 
hematopoietic stem cell disorder caused by a somatic mutation 
in phosphatidylinositol N-acetylglucosaminyltransferase 
subunit A (PIGA), whose gene product is required for the 
synthesis of glycosyl-phosphatidyl inositol (GPI) anchors (1). 
Loss of GPI anchors results in a deficiency of the protective 
complement inhibitors CD55 and CD59 on erythrocytes, 
thus making them susceptible to complement-mediated 
lysis. The clinical hallmarks of PNH include acquired 
hemolytic anemia, bone marrow failure and life-threatening 
thrombosis (2). Eculizumab, a monoclonal antibody that 
binds to the complement protein C5, protects PNH red 
cells from complement mediated intravascular hemolysis 
by inhibiting the formation of the membrane attack 
complex (C5–C9) (3,4). In two double-blind, randomized, 
placebo-controlled trials, eculizumab reduced intravascular 
hemolysis and improved quality of life in patients with 
PNH who received the drug (5,6). Although eculizumab has 
immunosuppressive properties, there is only one published 
case report of a malignancy (melanoma) developing on 
eculizumab (7). Although it is difficult to assess causality 
from individual case reports, it is helpful to see the spectrum 
of malignancies that occur in these patients. 
Case presentation
Currently we describe a patient who developed acute myeloid 
leukemia while on treatment with eculizumab. This case 
received a waiver of consent from the Institutional Review 
Board of New York Medical College, Valhalla, NY, USA.
A 71-year-old male with no significant past medical history 
presented to his primary care doctor in December 2013 with 
complaints of fatigue and dyspnea on exertion. A complete 
blood count (CBC) showed a white blood count (WBC) of 
5.8 × 109/L, hemoglobin of 13.1 gm/dL and a platelet count 
of 60 × 109/L. The patient was initially observed, however 
follow-up laboratories in February 2014 showed marked 
deterioration. The white blood count was 3.3 × 109/L with 
40% neutrophils, 56% lymphocytes and 4% monocytes, 
the hemoglobin was 7.7 gm/dL and the platelet count was 
8 × 109/L. The patient was referred to our center at that 
time. A bone marrow biopsy was hypoplastic (cellularity 
10%) with normal myeloid and megakaryocytic morphology. 
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There was a rare dysplastic erythroid cell (<10%) and a blast 
count of less than 1%. Flow cytometry and cytogenetics 
were normal, as was a myelodysplastic syndrome (MDS) 
FISH panel. An MDS next-generation sequencing panel that 
included ASXL1, RUNX1, EZH2, ETV6, and TP53 showed 
no mutations. Other laboratories, including reticulocyte 
count, Coombs, LDH, haptoglobin, folate, iron studies, 
hepatitis panel, and human immunodeficiency virus (HIV), 
parvovirus and Lyme serologies were unremarkable. His 
initial B12 level was low, however, he had no response to 
B12 injections. PNH testing showed that 0.1% of red cells 
lacked CD59 expression, and 5% of monocytes and 2% of 
granulocytes showed downregulation of CD59 and lack of 
FLAER expression. 
In March 2014, the patient was treated for aplastic 
anemia with anti-thymocyte globulin, 40 mg/kg daily 
for 4 days, steroids and cyclosporin. Only 2 months later 
the patient developed clinical evidence of intravascular 
hemolysis with rapid expansion of his PNH clone (red 
cells 0.25%, granulocytes 22%, monocytes 27%). After 
vaccination, he began therapy with eculizumab in July 
of 2014. He received ongoing therapy with eculizumab 
combined with cyclosporine and became transfusion in 
dependent with a normal WBC, hemoglobin of 11 gm/dL 
and peak platelet count of 71 × 109/L. 
In May of 2017, the patient was referred back to us 
for evaluation of worsening pancytopenia. His WBC was 
4.1 × 109/L with 23% neutrophils, 53% lymphocytes, 
16% monocytes, 1% eosinophils, 1% basophils, and 6% 
blasts. The hemoglobin was 9.4 gm/dL, and the platelet 
count was 19 × 109/L. A bone marrow biopsy showed 
acute myeloid leukemia with 55% blasts that expressed 
CD34, CD117, partial CD33, dim CD13, and HLA-DR. 
Cytogenetics demonstrated 46,XY,del[7](q22q34)[2]/46, 
XY[18]. Next-generation sequencing revealed mutations in 
PALB2 (c.311C>T; p.P104L, 50%), PHF6 (c.834+2T>G, 
52%),  and RUNX1  ( c .967_967+1insA,  10%, and 
c.593A>G; p.D198G, 22%). 
The patient was treated with CLAG-Ida (cladribine, 
cytarabine, granulocyte colony stimulating factor and 
idarubicin). On day 7 the patient developed neutropenic 
fever and received cefepime and vancomycin. A urine 
culture grew E. coli. On day 14 the patient suddenly 
developed septic shock and required intubation and pressor. 
Blood cultures grew vancomycin-resistant enterococcus 
and mold that was subsequently identified as Scedosporium 
prolificans. Despite maximal support the patient expired on 
day 17 of therapy.
Discussion
Eculizumab has changed the outcome of patients with 
PNH (8). In a report of the long-term results of eculizumab 
in 195 PNH patients who were treated over a 66-month 
period, only four deaths occurred, resulting in an estimated 
3-year survival rate of 97.6% (9). All patients demonstrated 
a reduction in LDH, and 96.4% of patients remained free 
of thromboembolic events. 
Eculizumab is a powerful inhibitor of the complement 
pathway. It is thus expected that immunological pathways 
that rely on complement activation could be adversely 
affected. For example, it is well documented that patients 
treated with eculizumab are at increased risk of infections, 
particularly Neisseria meningitidis infections (10). In the 
long-term study, 40 patients reported a total of 67 serious 
infections, including two cases of meningococcal sepsis (9). 
These infections can occur even after appropriate 
vaccination and are similar to those seen in patients with 
hereditary disorders of complement (11). 
Classically, T-cell immunity is thought to be the primary 
host defense mechanism preventing the development 
and propagation of malignant diseases. More recently, a 
relationship between imbalanced complement activation in 
the tumor microenvironment and suppression of antitumor 
immune responses has been discovered (12). Despite these 
findings, there are only limited reports of malignancies 
occurring in patients treated with eculizumab. In the long-
term study, one patient developed MDS and was taken 
off study to pursue a stem cell transplant (9). Manganoni 
et al. reported a patient who developed two melanomas 
simultaneously after having received eculizumab for 6 years 
as treatment of PNH (7). There was no family history of 
skin cancers and no prior dysplastic nevi in this patient. 
Further post marketing studies are needed to determine 
the incidence of malignancies in patients treated with 
eculizumab.
Progression to acute myeloid leukemia is a known 
complication of aplastic anemia in patients treated with 
immunosuppressive therapy. On average, the incidence 
of MDS and acute myelocytic leukemia (AML) after 
immunosuppressive therapy ranges from 5–15% after a 
follow-up of 5–11 years (13,14). In our case, the presence 
of a PNH clone at diagnosis was evidence of clonal disease 
from the start, even though the patient did not meet 
diagnostic criteria for MDS at that time. It is unknown if 
eculizumab could have influenced the rapidity with which 
our patient progressed to AML.
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Our patient expired from Scedosporium sepsis very early 
into his treatment course. Although there are many reports 
of Scedosporium infection occurring in leukemia patients 
undergoing induction therapy or allogeneic stem cell 
transplantation, these life threatening fungal infections 
are more common in patients with multiply-relapsed 
disease, and in those who have either been neutropenic 
for prolonged periods of time, or in those receiving T-cell 
suppressing therapies after transplant (15). It is unknown 
whether pretreatment with eculizumab increased our 
patient’s risk of developing a relatively rare disseminated 
fungal infection so early in his treatment course. 
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